Cargando…
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
PURPOSE: Infliximab, a monoclonal antibody, is approved for the treatment of inflammatory diseases at doses that depend on the patient disease population. It was the aim of this study to evaluate its population pharmacokinetics in patients with moderately to severely active ulcerative colitis and ch...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Springer-Verlag
2009
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778780/ https://www.ncbi.nlm.nih.gov/pubmed/19756557 http://dx.doi.org/10.1007/s00228-009-0718-4 |